Regimmune, Pfizer, JDRF deal

Regimmune, JDRF and Pfizer partnered to develop an antigen-specific immunotherapy using Regimmune’s a-GalCer/liposome platform to treat Type I diabetes. Regimmune will develop the antigen-specific the...